- Home
- YGMZ vs CRBP Comparison
YGMZ vs CRBP Comparison
Compare YGMZ & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YGMZ
- CRBP
- Stock Information
- Founded
- YGMZ 2002
- CRBP 2009
- Country
- YGMZ China
- CRBP United States
- Employees
- YGMZ N/A
- CRBP N/A
- Industry
- YGMZ Transportation Services
- CRBP Biotechnology: Pharmaceutical Preparations
- Sector
- YGMZ Consumer Discretionary
- CRBP Health Care
- Exchange
- YGMZ Nasdaq
- CRBP Nasdaq
- Market Cap
- YGMZ N/A
- CRBP 73.4M
- IPO Year
- YGMZ 2020
- CRBP N/A
- Fundamental
- Price
- YGMZ $0.76
- CRBP $5.03
- Analyst Decision
- YGMZ
- CRBP Strong Buy
- Analyst Count
- YGMZ 0
- CRBP 10
- Target Price
- YGMZ N/A
- CRBP $60.89
- AVG Volume (30 Days)
- YGMZ 39.9K
- CRBP 211.7K
- Earning Date
- YGMZ 01-01-0001
- CRBP 03-11-2025
- Dividend Yield
- YGMZ N/A
- CRBP N/A
- EPS Growth
- YGMZ N/A
- CRBP N/A
- EPS
- YGMZ N/A
- CRBP N/A
- Revenue
- YGMZ $55,805,416.00
- CRBP N/A
- Revenue This Year
- YGMZ N/A
- CRBP N/A
- Revenue Next Year
- YGMZ N/A
- CRBP $270.01
- P/E Ratio
- YGMZ N/A
- CRBP N/A
- Revenue Growth
- YGMZ N/A
- CRBP N/A
- 52 Week Low
- YGMZ $0.64
- CRBP $4.92
- 52 Week High
- YGMZ $4.35
- CRBP $61.90
- Technical
- Relative Strength Index (RSI)
- YGMZ 40.22
- CRBP 25.32
- Support Level
- YGMZ $0.75
- CRBP $5.76
- Resistance Level
- YGMZ $0.99
- CRBP $6.17
- Average True Range (ATR)
- YGMZ 0.10
- CRBP 0.40
- MACD
- YGMZ -0.02
- CRBP 0.01
- Stochastic Oscillator
- YGMZ 1.49
- CRBP 5.33
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.